RxDoctor Payments DataLook up a doctor →

Peder Pedersen, MD

Gastroenterology · Salt Lake City, UTNPI 1568558211

Payments from drug & device makers

$1,046,693in general payments, 2019–2025

Across 306 payments — averaging $3420.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$647K
  • Janssen Research & Development, LLC$193K
  • Teva Pharmaceuticals USA, Inc.$120K
  • AbbVie$58K
  • Ironwood Pharmaceuticals, Inc$14K
  • Braintree Laboratories, Inc.$8K
  • plus $6K from 11 others
$45,092in research payments, 2019–2025

Across 8 payments — averaging $5636.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$45K

What the payments were for

  • Food & beverage$673100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,046,693 in reported general payments places this provider in the 90th percentile of 122 gastroenterology providers in Utah.

See all gastroenterology providers in Utah

Medicare billing

Part B allowed, 2024
$136,063
Medicare patients
271
Services billed
3,427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab19$533,354
OcalivaObeticholic Acid13$120,531
Cimzia (2 Pack)Certolizumab Pegol13$79,586
Mesalamine20$11,441
Balsalazide Disodium13$3,669
Azathioprine31$2,653
Omeprazole103$1,780
Budesonide DrBudesonide12$1,549
Pantoprazole Sodium78$1,037
Sulfasalazine20$928
Esomeprazole Magnesium12$439
Ondansetron OdtOndansetron12$158

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$326$533,35419 claims
Intercept Pharmaceuticals, Inc.Ocaliva$12$120,53113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 122 gastroenterology providers in Utah.

Other gastroenterology in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →